Antiandrogens with marginal agonist activity and methods of use
CA 2522784 C · Owner: Hollis-Eden Pharmaceuticals, Inc. · Inventors: Marwah, Padma; Lardy, Henry A.; Marwah, Ashok K.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The instant invention provides potent antiandrogen compounds such as 3.beta. -, acetoxyandrost-1,5-diene-17-ethylene ketal and 3.beta.-hydroxyandrost-1 5-, diene-17ethylene ketal, and methods for their use in the prevention and treatment of biological conditions mediated by androgen receptors. Thus for , example, compounds of the invention are useful in the prevention and treatment of prostrate cancer. Furthermore, it has been discovered that compounds of the invention are useful in the prevention and treatment of androgen-independent cancers such as androgen-independent prostrate cancer. Finally inventive , compounds may be used to treat antiandrogen induced withdrawal syndrome.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 30, 2004 and granted June 19, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 30, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 30, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.